Physician profile
Lance Young
NPI 1396426391
$1,541.93
in general payments reported to CMS, 2019-2025
18 companies · $609 in 2025
The $609 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.75 · 2024: $869 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $308.00 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Astrazeneca Pharmaceuticals LP | $142.50 | 2024 | Lynparza, Calquence |
| Springworks Therapeutics, INC. | $134.15 | 2024-2025 | Ogsiveo |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Orgovyx |
| Pfizer INC. | $123.92 | 2024 | |
| Jazz Pharmaceuticals INC. | $119.83 | 2024 | |
| Tempus Ai, INC | $108.67 | 2024-2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $96.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $68.39 | 2023-2024 | |
| Genzyme Corporation | $57.93 | 2025 | |
| Janssen Biotech, INC. | $56.57 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $48.27 | 2025 | Keytruda |
| Aadi Bioscience, INC. | $32.74 | 2025 | Fyarro |
| Takeda Pharmaceuticals U.S.A., INC. | $31.76 | 2024 | Iclusig |
| Sobi, INC | $27.38 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $20.34 | 2025 | |
| Alnylam Pharmaceuticals INC. | $20.06 | 2025 | Givlaari |
| Abbvie INC. | $19.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.